Supplementary Figure S2 from CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1

Yunqin Lee,June Ho Shin,Michelle Longmire,Hua Wang,Holbrook E. Kohrt,Howard Y. Chang,John B. Sunwoo

DOI: https://doi.org/10.1158/1078-0432.22455255

2023-01-01

Abstract:Supplementary Figure S2. Characterization of CD44- and CD44+ SCCHN cells.

What problem does this paper attempt to address?

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Tao Jiang,Qiqi Jin,Jiahao Wang,Fengying Wu,Jian Chen,Gongyan Chen,Yunchao Huang,Jianhua Chen,Ying Cheng,QiMing Wang,Yueyin Pan,Jianying Zhou,Jianhua Shi,Xingxiang Xu,LiZhu Lin,Wei Zhang,Yiping Zhang,Yunpeng Liu,Yong Fang,Jifeng Feng,Zhehai Wang,Sheng Hu,Jian Fang,Yongqian Shu,Jiuwei Cui,Yi Hu,Wenxiu Yao,Xingya Li,Xiaoyan Lin,Rui Wang,Yongsheng Wang,Wei Shi,Gaohua Feng,Jun Ni,Beibei Mao,Dandan Ren,Huaibo Sun,Henghui Zhang,Luonan Chen,Caicun Zhou,Shengxiang Ren

DOI: https://doi.org/10.1158/1078-0432.23791953.v1

2023-01-01

Abstract:Supplementary Materials
CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Jianya Zhou,Wenjia Sun,Xun Zeng,Jing Zheng,Jingjing Qu,Nan Jiang,Jianying Zhou

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e21189

IF: 45.3

2023-01-01

Journal of Clinical Oncology

Abstract:e21189 Background: Immune checkpoint inhibitors (ICIs) are currently widely used and have made significant advances in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Despite available biomarker stratification, clinical responses vary. Thus, potential biomarkers for identifying patients who will benefit from the immunotherapy are urgently needed. Methods: We applied mass cytometry (CyTOF) to deeply analyze the association of cell subpopulations in PBMC before and after single-agent immunotherapy with clinical outcomes in advanced NSCLC. We then performed flow cytometry of peripheral blood and multiplex immunohistochemistry/immunofluorescence (mIHC/IF) of tumor samples to validate our conclusion. In addition, RNA sequencing (RNA-seq) was performed to explore the mechanism of the ICIs treatment efficacy of NSCLC. Results: In a prospective cohort (n = 20), high CD57+ CD8+ T cell proportion in PBMC detected by CyTOF was associated with good response ( p= 0.014) in advanced NSCLC patients. The result was confirmed in an independent, prospective cohort (n = 30) using flow cytometry, and the specificity and sensitivity of flow cytometry was then assessed in this cohort. CD57+CD8+ T cell proportion, as determined by flow cytometry, successfully stratified responders and non-responders to ICIs ( P< 0.001). We also confirmed this result in FFPE samples (n = 31) ( p= 0.004). In addition, transcriptomic differences between CD57+CD8+ T cells and CD57-CD8+ T cells were found performed by RNA sequencing (RNA-seq). Conclusions: Our results suggest that CD57+CD8+ T cell proportion may serve as a predictive value of response to PD-1/PD-L1 checkpoint blockade. Further validation in additional NSCLC cohorts is warranted.
[Quantitative Studies on Expression of Peripheral Blood CD44 and CD54 in Non-Small Cell Lung Carcinoma].

Q Chen,J Zhou,Y Wu

DOI: https://doi.org/10.3760/j:issn:1001-0939.2001.10.009

2001-01-01

Abstract:OBJECTIVE:To assess the relationship between expression of peripheral blood CD44 and CD54 in lymphocyte with non-small cell lung cancer and clinicopathological features. METHODS:Peripheral blood CD44 contents in 50 patients with lung cancer were detected by flow-cytometry, 30 normal donors and 25 patients with benign lesions served as controls. RESULTS:Peripheral blood CD44 and CD54 in lymphocyte with lung cancer were significantly higher than those in benign lesions and normal controls (P < 0.01). There is no distinct difference between CD44 and CD54 in benign lesions and normal controls (P > 0.05). Lung cancer with lymph node metastasis showed higher expression of CD44 and CD54 than lung cancer without lymph node metastasis (P < 0.01). Distinctly statistic difference was showed between CD44 in stage III, IV and stage I, II (P < 0.01). CD54 content in stage IV was higher than that in stage I, II and III, respectively. Histopathological grade was significantly associated with the expression of CD44 and CD54. Peripheral blood CD44 and CD54 contents were not related with squamous cell carcinoma and adenocarcinoma. CONCLUSION:Detection of CD44 and CD54 levels by flow cytometry might be used as a marker to evaluate prognosis and metastasis in patients with non-small cell lung cancer.
Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951174

2024-01-01

Abstract:Supplementary Figure S5. Characterization of PD-1+ and PD-1- CD4+ T cells in PB and tumor.
Supplemental Figure S2 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402082

2023-01-01

Abstract:CCDC134 has no apparent effect on activation, effector function and proliferation of mouse CD4+ T cells.
Supplementary Table S8 from CD38-Mediated Immunosuppression As a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Limo Chen,Lixia Diao,Yongyi Yang,Xiaohui Yi,B. Leticia Rodriguez,Yanli Li,Pamela Villalobos,Tina Cascone,Xi Liu,Tao Lin,Philip L. Lorenzi,Anfei Huang,Qiang Zhang,Di Peng,Jared J. Fradette,David H. Peng,Christin Ungewiss,Jonathon D. Roybal,Pan Tong,Junna Oba,Ferdinandos Skoulidis,Weiyi Peng,Brett W. Carter,Carl M. Gay,Fan Yu,Caleb A. Class,Jianxin Zhu,Jaime Rodriguez‐Canales,Masanori Kawakami,Lauren A. Byers,Scott E. Woodman,Vassiliki A. Papadimitrakopoulou,Ethan Dmitrovsky,Jing Wang,Stephen E. Ullrich,Ignacio I. Wistuba,John V. Heymach,F. Xiao-Feng Qin,Don L. Gibbons

DOI: https://doi.org/10.1158/2159-8290.22532330

2023-01-01

Abstract:Patient sample information as well as CD38 and PD-L1 IHC score in lung cancer tissue microarray bank TMA4.
Supplementary Figure S1 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142144

2024-01-01

Abstract:Supplementary Figure S1. CCL22-expressing cDC are associated with worse survival in cancer patients
Supplementary Data from CD19-specific CAR T Cells That Express a PD-1/CD28 Chimeric Switch-Receptor Are Effective in Patients with PD-L1–positive B-Cell Lymphoma

Hui Liu,Wen Lei,Chaoting Zhang,Chunmei Yang,Juying Wei,Qunyi Guo,Xiaojun Guo,Zhilu Chen,Ying Lu,Ken H. Young,Zheming Lu,Wenbin Qian

DOI: https://doi.org/10.1158/1078-0432.23586761.v1

2023-01-01

Abstract:Supplementary Data from CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma
Supplementary Figure from Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade

Wei Wang,Taja Lozar,Athena E. Golfinos,Denis Lee,Ellery Gronski,Ella Ward-Shaw,Mitchell Hayes,Justine Y. Bruce,Randall J. Kimple,Rong Hu,Paul M. Harari,Jin Xu,Aysenur Keske,Paul M. Sondel,Megan B. Fitzpatrick,Huy Q. Dinh,Paul F. Lambert

DOI: https://doi.org/10.1158/1078-0432.22487147

2023-01-01

Abstract:Supplementary Figure from Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade
Supplementary Figure 1 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Guangcun Cheng,Xueqing Sun,Jinglong Wang,Gang Xiao,Xiumin Wang,Xuemei Fan,Lidong Zu,Mingang Hao,Qing Qu,Yan Mao,Yunjing Xue,Jianhua Wang

DOI: https://doi.org/10.1158/0008-5472.22401690

2023-01-01

Abstract:PDF file - 623K, Effects of restoring HIC1 expression in MDA-468 cells.
Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399947.v1

2023-01-01

Abstract:PDF file - 31KB, Supplementary Figure 2 Determination of concentration of IL-6 and IL-10 within tumor.
Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402073

2023-01-01

Abstract:Involvement of CD4+ T cells in the induction of antitumor activity by CCDC134.
Supplementary Figure 6 from Reciprocal Interactions Between Tumor-Associated Macrophages and CD44-Positive Cancer Cells Via Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer

Guanhua Rao,Hongyi Wang,Baowei Li,Li Huang,Danfeng Xue,Xiaohui Wang,Haijing Jin,Jun Wang,Yushan Zhu,Youyong Lu,Lei Du,Quan Chen

DOI: https://doi.org/10.1158/1078-0432.22449576.v1

2023-01-01

Abstract:PDF file - 1587K, Kaplan-Meier curves of survival rate for 190 patients.
Supplementary Figure 2 from Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis

Kristin K. Deeb,Aleksandra M. Michalowska,Cheol-yong Yoon,Scott M. Krummey,Mark J. Hoenerhoff,Claudine Kavanaugh,Ming-chung Li,Francesco J. Demayo,Ilona Linnoila,Chu-xia Deng,Eva Y-H.P. Lee,Daniel Medina,Joanna H. Shih,Jeffrey E. Green

DOI: https://doi.org/10.1158/0008-5472.22368605

2023-01-01

Abstract:Supplementary Figure 2 from Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis
Supplementary Data from the Mechanism of Anti–PD-L1 Antibody Efficacy Against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 As a Cytolytic Effector

Wenjuan Dong,Xiaojin Wu,Shoubao Ma,Yufeng Wang,Ansel P. Nalin,Zheng Zhu,Jianying Zhang,Don M. Benson,Kai He,Michael A. Caligiuri,Jianhua Yu

DOI: https://doi.org/10.1158/2159-8290.22532669.v1

2023-01-01

Abstract:Supplementary figures and figure legends as well as supplementary methods and materials
Supplemental Figure S4 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Jing Huang,Lin Xiao,Xiaoting Gong,Wenwei Shao,Yanhui Yin,Qinyuan Liao,Yang Meng,Yingmei Zhang,Dalong Ma,Xiaoyan Qiu

DOI: https://doi.org/10.1158/0008-5472.22402076.v1

2023-01-01

Abstract:Potent antitumor activity of CCDC134 in vivo.
Supplementary Fig S4 from CD36+ Proinflammatory Macrophages Interact with ZCCHC12+ Tumor Cells in Papillary Thyroid Cancer Promoting Tumor Progression and Recurrence

Xin Zhang,Limei Guo,Wenyu Tian,Ying Yang,Yue Yin,Yaruo Qiu,Weixuan Wang,Yang Li,Guangze Zhang,Xuyang Zhao,Guangxi Wang,Zhiqiang Lin,Meng Yang,Wei Zhao,Dan Lu

DOI: https://doi.org/10.1158/2326-6066.27601882

2024-01-01

Abstract:Supplementary Table S4 The relationship between SPP1 expression and clinicpathologic characteristics in patients with PTC.
Supplementary Figure S2 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Jason Bugno,Liangliang Wang,Xianbin Yu,Xuezhi Cao,Jiaai Wang,Xiaona Huang,Kaiting Yang,Andras Piffko,Katherine Chen,Stephen Y. Luo,Emile Naccasha,Yuzhu Hou,Sherry Fu,Chuan He,Yang-xin Fu,Hua L. Liang,Ralph R. Weichselbaum

DOI: https://doi.org/10.1158/1078-0432.27142138

2024-01-01

Abstract:Supplementary Figure S2. Flow cytometric characterization of tumor cDC after local radiation
Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma

Ross J Turner,Thomas V Guy,Nicholas J Geraghty,Ashleigh Splitt,Debbie Watson,Daniel Brungs,Martin G Carolan,Andrew A Miller,Jeremiah F de Leon,Morteza Aghmesheh,Ronald Sluyter

DOI: https://doi.org/10.3390/ijms241612538

2023-08-08

Abstract:The ectonucleotidases CD39 and CD73 are present on immune cells and play important roles in cancer progression by suppressing antitumour immunity. As such, CD39 and CD73 on peripheral blood mononuclear cells (PBMCs) are emerging as potential biomarkers to predict disease outcomes and treatment responses in cancer patients. This study aimed to examine T and B cells, including CD39 and CD73 expressing subsets, by flow cytometry in PBMCs from 28 patients with head and neck squamous cell carcinoma (HNSCC) and to assess the correlation with the treatment modality, human papillomavirus (HPV) status, and relapse-free survival (RFS). The PBMCs were examined pre-, mid-, and post-radiotherapy with concurrent cisplatin chemotherapy or anti-epidermal growth factor receptor antibody (cetuximab) therapy. Combination radiotherapy caused changes to T and B cell populations, including CD39 and CD73 expressing subsets, but no such differences were observed between concurrent chemotherapy and cetuximab. Pretreatment PBMCs from HPV+ patients contained increased proportions of CD39-CD73-CD4+ T cells and reduced proportions of CD39-/+CD73+CD4+ T cells compared to the equivalent cells from HPV- patients. Notably, the pretreatment CD4+:CD8+ T cell ratios and CD39+CD73+CD19+ B cell proportions below the respective cohort medians corresponded with an improved RFS. Collectively, this study supports the notion that CD39 and CD73 may contribute to disease outcomes in HNSCC patients and may assist as biomarkers, either alone or as part of immune signatures, in HNSCC. Further studies of CD39 and CD73 on PBMCs from larger cohorts of HNSCC patients are warranted.

Supplementary Figure S2 from CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

[Quantitative Studies on Expression of Peripheral Blood CD44 and CD54 in Non-Small Cell Lung Carcinoma].

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplemental Figure S2 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplementary Table S8 from CD38-Mediated Immunosuppression As a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Supplementary Figure S1 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Data from CD19-specific CAR T Cells That Express a PD-1/CD28 Chimeric Switch-Receptor Are Effective in Patients with PD-L1–positive B-Cell Lymphoma

Supplementary Figure from Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade

Supplementary Figure 1 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplementary Figure 6 from Reciprocal Interactions Between Tumor-Associated Macrophages and CD44-Positive Cancer Cells Via Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer

Supplementary Figure 2 from Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis

Supplementary Data from the Mechanism of Anti–PD-L1 Antibody Efficacy Against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 As a Cytolytic Effector

Supplemental Figure S4 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplementary Fig S4 from CD36+ Proinflammatory Macrophages Interact with ZCCHC12+ Tumor Cells in Papillary Thyroid Cancer Promoting Tumor Progression and Recurrence

Supplementary Figure S2 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma